Lwona Dobler (Iwona Pawlikowska-Dobler)

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 2

Top Topics

Prognostic Factors

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Targeted oncology

Takeda Pharmaceuticals USA Inc

University of Silesia (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Takeda Pharmaceuticals USA Inc Feb 22 2016

United States

Principal Statistician :: Global Biostatistics

Education History

University of Silesia Oct 01 1997

Poland

PHD :: Mathematics

Publications

Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V Faller, Lwona Dobler, Neeraj Gupta, Farhad Sedarati, Kyu-Pyo Kim
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. Targeted oncology (2021)
Ronan T Swords, Steven Coutre, Michael B Maris, Joshua F Zeidner, James M Foran, Jose Cruz, Harry P Erba, Jesus G Berdeja, Wayne Tam, Saran Vardhanabhuti, Lwona Dobler, Hélène M Faessel, Ajeeta B Dash, Farhad Sedarati, Douglas V Faller, Michael R Savona
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood 131 (13) (2018)